S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
NASDAQ:ICAD

iCAD - ICAD Stock Forecast, Price & News

$3.81
-0.17 (-4.27%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.64
$3.98
50-Day Range
$3.64
$4.56
52-Week Range
$2.91
$12.73
Volume
81,421 shs
Average Volume
200,752 shs
Market Capitalization
$95.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

iCAD MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
228.1% Upside
$12.50 Price Target
Short Interest
Healthy
3.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of iCAD in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Computer And Technology Sector

326th out of 644 stocks

Surgical & Medical Instruments Industry

43rd out of 112 stocks

ICAD stock logo

About iCAD (NASDAQ:ICAD) Stock

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Analysts Set New Price Targets

Separately, BTIG Research lowered their price objective on iCAD from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, June 24th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.50.

iCAD Stock Performance

Shares of iCAD stock opened at $3.81 on Wednesday. The firm has a market cap of $95.94 million, a PE ratio of -7.19 and a beta of 1.08. iCAD has a 1 year low of $2.91 and a 1 year high of $12.73. The firm's 50-day simple moving average is $4.07 and its 200-day simple moving average is $4.19.

iCAD (NASDAQ:ICAD - Get Rating) last posted its earnings results on Wednesday, May 11th. The technology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.04). iCAD had a negative return on equity of 26.45% and a negative net margin of 40.43%. The firm had revenue of $7.52 million during the quarter, compared to the consensus estimate of $7.50 million. On average, equities analysts predict that iCAD will post -0.57 earnings per share for the current year.

Receive ICAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

ICAD Stock News Headlines

Earnings Outlook For icad
iCAD (ICAD) Set to Announce Quarterly Earnings on Wednesday
5 Growth Stocks to Buy Now - InvestorPlace
See More Headlines
Receive ICAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

ICAD Company Calendar

Last Earnings
11/09/2021
Today
8/10/2022
Next Earnings (Confirmed)
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:ICAD
Employees
136
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+228.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-11,240,000.00
Pretax Margin
-40.42%

Debt

Sales & Book Value

Annual Sales
$33.64 million
Book Value
$1.85 per share

Miscellaneous

Free Float
22,034,000
Market Cap
$95.94 million
Optionable
Optionable
Beta
1.08

Social Links















ICAD Stock - Frequently Asked Questions

Should I buy or sell iCAD stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICAD shares.
View ICAD analyst ratings
or view top-rated stocks.

What is iCAD's stock price forecast for 2022?

5 Wall Street analysts have issued 12-month price objectives for iCAD's shares. Their ICAD share price forecasts range from $8.00 to $16.00. On average, they predict the company's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 228.1% from the stock's current price.
View analysts price targets for ICAD
or view top-rated stocks among Wall Street analysts.

How has iCAD's stock price performed in 2022?

iCAD's stock was trading at $7.20 at the beginning of the year. Since then, ICAD stock has decreased by 47.1% and is now trading at $3.81.
View the best growth stocks for 2022 here
.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our ICAD earnings forecast
.

How can I listen to iCAD's earnings call?

iCAD will be holding an earnings conference call on Wednesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) announced its earnings results on Tuesday, November, 9th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.01. The technology company had revenue of $9.36 million for the quarter, compared to the consensus estimate of $9.41 million. iCAD had a negative trailing twelve-month return on equity of 26.45% and a negative net margin of 40.43%. During the same quarter in the prior year, the business earned ($0.08) EPS.

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD Chief Executive Officer Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among the company's employees.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by many different institutional and retail investors. Top institutional shareholders include General American Investors Co. Inc. (0.76%), Oak Family Advisors LLC (0.42%) and Walleye Capital LLC (0.17%). Insiders that own company stock include Andy Sassine, Charles Ross Carter, Jonathan Go, Michael S Klein, R Scott Areglado, Stacey M Stevens, Susan Alyson Wood and Timothy Norris Irish.
View institutional ownership trends
.

How do I buy shares of iCAD?

Shares of ICAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $3.81.

How much money does iCAD make?

iCAD (NASDAQ:ICAD) has a market capitalization of $95.94 million and generates $33.64 million in revenue each year. The technology company earns $-11,240,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

How many employees does iCAD have?

iCAD employs 136 workers across the globe.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The official website for the company is www.icadmed.com. The technology company can be reached via phone at (603) 882-5200, via email at jeremy@lifesciadvisors.com, or via fax at 603-880-3843.

This page (NASDAQ:ICAD) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.